Emerging issues related to COVID-19 vaccination in patients with cancer
Kamal S. Saini, Diogo Martins-Branco, Marco Tagliamento, Laura Vidal, Navneet Singh, Kevin Punie, Monika Lamba Saini, Isagani Chico, Giuseppe Curigliano, Evandro de Azambuja, Matteo Lambertini
Abstract
Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more severe clinical course following the infection. The rollout of COVID-19 vaccines in many parts of the world has raised hopes of controlling the pandemic. In this editorial, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer.